Stacey Titus • July 9, 2024
HCMA West Coast Tour

Lisa Salberg, CEO and Founder, and I will host two Meet and Greets during our travel on the West Coast in July!

La Jolla, CA, “Meet and Greet” on Thursday, July 18th,  at Olive & Basil from 6:00 – 8:00 PM PT.  Space is limited, so we ask all to register by July 16th for proper headcount and to ensure enough space is reserved.   Venue details: Olive & Basil, 8008 Girard Ave #220, La Jolla, CA 92037.  For additional information and to register for the La Jolla Meet and Greet, click here:  https://4hcm.org/inspire_events/la-jolla-meet-greet/

Seattle, WA “Meet and Greet” on Tuesday, July 23rd,  at Ivar’s Salmon House from 6:30 – 8:30 PM PT.   Space is limited, so we ask all to register by July 21st for proper headcount and ensure enough space is reserved. Venue information:  Ivar’s Salmon House, 401 Northeast Northlake Way, Seattle, WA 98105. For more details and to register for the Seattle Meet and Greet, click here:   https://4hcm.org/inspire_events/seattle-meet-greet/

Our Meet and Greets require registration, although there is no registration charge. A light dinner menu and non-alcoholic beverages will be served at each event.

We are looking forward to seeing you in person!

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts